ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine

Guo, Chong; Song, Chaoying; Zhang, Jiali; Gao, Yisong; Qi, Yuying; Zhao, Zongyao; Yuan, Chengfu*china three gorges univ
Genes & Diseases2022-5DOI: 10.1016/j.gendis.2020.11.017
10被引6阅读
引用收藏
分享

摘要

Among the gynecological cancers, ovarian cancer is the most lethal. Its therapeutic options include a combination of chemotherapy with platinum-based compounds and cytoreductive surgery. Most ovarian cancer patients exhibit an initial response to platinum-based therapy, however, platinum resistance has led to up to 80% of this responsive cohort becoming refractory. Ovarian cancer recurrence and drug resistance to current chemotherapeutic options is a global challenge. Chemo-resistance is a complex phenomenon that involves multiple genes and signal transduction pathways. Therefore, it is important to elucidate on the underlying molecular mechanisms involved in chemo-resistance. This inform decisions regarding therapeutic management and help in the identification of novel and effective drug targets. Studies have documented the individual biomarkers of platinum-resistance in ovarian cancer that are potential therapeutic targets. This review summarizes the molecular mechanisms of platinum resistance in ovarian cancer, novel drug targets, and clinical outcomes.

学科与关键词

关键词
Clinical outcomesMechanismsMolecular biomarkersOvarian cancerPlatinum resistance
相关
加载中…
  • A Novel Platinum Resistance-Related Immune Gene Signature for Overall Survival Prediction in Patients with Ovarian Cancer
    Zhou, Chenfei; Ma, Junnan; Luo, Wanjun; Hu, Jiemei; Chen, Jing; Liang, Suiying; He, Shanyang*Biochemical Genetics, 2024, 62(1): 112-124.
  • Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
    C Zeller; W Dai; N L Steele; A Siddiq; A J Walley; C S M Wilhelm-Benartzi; S Rizzo; A van der Zee; J A Plumb; R BrownOncogene, 2012, 31(Suppl 2).
  • Is Autophagy Always a Barrier to Cisplatin Therapy?
    Xu, Jingwen; Gewirtz, David A.*Biomolecules, 2022, 12(3): 463.被引 21
查看全部 →

发表信息

论文状态
公开发表
期刊
Genes & Diseases
发表日期
2022-05
卷期
第 9 卷, 第 3 期
页码
668-681
DOI
10.1016/j.gendis.2020.11.017
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81773959, 81974528]; Open Foundation for Tumor Microenvironment and Immunotherapy Key Laboratory of Hubei province in China [2019KZL09]; Health commission of Hubei Province scientific research project [WJ2019H527, 2020ZYYD016]

作者

  • G

    Guo, Chong (第一作者)

    china three gorges univ

  • S

    Song, Chaoying

    china three gorges univ

查看全部 7 位作者收起作者
  • Z

    Zhang, Jiali

    china three gorges univ

  • G

    Gao, Yisong

    china three gorges univ

  • Q

    Qi, Yuying

    china three gorges univ

  • Z

    Zhao, Zongyao

    china three gorges univ

  • Y

    Yuan, Chengfu (通讯)

    china three gorges univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417